Compugen (CGEN) Competitors $1.43 -0.01 (-0.69%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CGEN vs. BDTX, CHRS, TCRR, INBX, ITOS, GLUE, PRTC, TERN, GHRS, and MREOShould you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Black Diamond Therapeutics (BDTX), Coherus BioSciences (CHRS), TCR2 Therapeutics (TCRR), Inhibrx (INBX), iTeos Therapeutics (ITOS), Monte Rosa Therapeutics (GLUE), PureTech Health (PRTC), Terns Pharmaceuticals (TERN), GH Research (GHRS), and Mereo BioPharma Group (MREO). These companies are all part of the "medical" sector. Compugen vs. Black Diamond Therapeutics Coherus BioSciences TCR2 Therapeutics Inhibrx iTeos Therapeutics Monte Rosa Therapeutics PureTech Health Terns Pharmaceuticals GH Research Mereo BioPharma Group Compugen (NASDAQ:CGEN) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking. Do insiders and institutionals hold more shares of CGEN or BDTX? 12.2% of Compugen shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer CGEN or BDTX? Compugen received 257 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. However, 69.86% of users gave Black Diamond Therapeutics an outperform vote while only 64.30% of users gave Compugen an outperform vote. CompanyUnderperformOutperformCompugenOutperform Votes30864.30% Underperform Votes17135.70% Black Diamond TherapeuticsOutperform Votes5169.86% Underperform Votes2230.14% Which has better earnings & valuation, CGEN or BDTX? Compugen has higher revenue and earnings than Black Diamond Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$33.46M3.81-$18.75M$0.0271.50Black Diamond TherapeuticsN/AN/A-$82.44M-$1.33-1.83 Is CGEN or BDTX more profitable? Compugen has a net margin of 2.67% compared to Black Diamond Therapeutics' net margin of 0.00%. Compugen's return on equity of 2.62% beat Black Diamond Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Compugen2.67% 2.62% 1.36% Black Diamond Therapeutics N/A -68.08%-49.65% Does the media refer more to CGEN or BDTX? In the previous week, Compugen had 2 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 3 mentions for Compugen and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.92 beat Compugen's score of 1.02 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer CGEN or BDTX? Compugen currently has a consensus price target of $4.00, indicating a potential upside of 179.72%. Black Diamond Therapeutics has a consensus price target of $15.50, indicating a potential upside of 537.86%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, CGEN or BDTX? Compugen has a beta of 2.64, indicating that its stock price is 164% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.51, indicating that its stock price is 151% more volatile than the S&P 500. SummaryCompugen beats Black Diamond Therapeutics on 11 of the 16 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Compugen News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEN vs. The Competition Export to ExcelMetricCompugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$128.50M$2.93B$5.07B$8.90BDividend YieldN/A1.91%4.99%4.07%P/E Ratio71.5016.1687.8613.46Price / Sales3.81282.771,228.8287.66Price / CashN/A169.3839.5136.27Price / Book2.104.436.946.30Net Income-$18.75M-$41.63M$119.12M$225.93M7 Day Performance-4.03%-4.73%-1.84%-1.32%1 Month Performance-16.37%-6.53%-3.65%0.60%1 Year Performance116.04%25.63%31.64%26.23% Compugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGENCompugen2.7226 of 5 stars$1.43-0.7%$4.00+179.7%+121.5%$128.50M$33.46M71.5068BDTXBlack Diamond Therapeutics2.8436 of 5 stars$2.43-4.7%$15.50+537.9%+8.0%$144.29MN/A0.0090Positive NewsCHRSCoherus BioSciences3.8289 of 5 stars$1.10+34.1%$6.13+456.8%-46.9%$94.65M$257.24M0.00246High Trading VolumeTCRRTCR2 TherapeuticsN/A$1.48-5.7%N/A+0.0%$58.11MN/A-0.35137High Trading VolumeINBXInhibrx1.2884 of 5 stars$14.04-1.7%N/A-36.9%$206.86M$1.63M0.00166ITOSiTeos Therapeutics3.4955 of 5 stars$7.85-0.6%$31.50+301.3%-23.0%$288.62M$12.60M0.0090GLUEMonte Rosa Therapeutics2.9578 of 5 stars$8.36+0.6%$16.00+91.4%+157.2%$510.54MN/A0.0090PRTCPureTech Health2.2392 of 5 stars$21.70+2.1%$45.00+107.4%+0.9%$508.96M$3.33M0.00100Analyst RevisionNews CoveragePositive NewsTERNTerns Pharmaceuticals4.327 of 5 stars$5.60-5.2%$27.25+386.6%+49.3%$501.99M$1M0.0040GHRSGH Research1.3894 of 5 stars$10.95+13.9%$35.67+225.7%+77.2%$499.99MN/A0.0010Analyst ForecastMREOMereo BioPharma Group2.9665 of 5 stars$3.58+2.6%$7.50+109.5%+63.5%$489.50M$10M0.0040Analyst RevisionNews Coverage Related Companies and Tools Related Companies Black Diamond Therapeutics Alternatives Coherus BioSciences Alternatives TCR2 Therapeutics Alternatives Inhibrx Alternatives iTeos Therapeutics Alternatives Monte Rosa Therapeutics Alternatives PureTech Health Alternatives Terns Pharmaceuticals Alternatives GH Research Alternatives Mereo BioPharma Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CGEN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGEN Stock Alerts